Switching immunoglobulin products, what are the implications? Result of 2018 census of immunology centres

The use of regular infusions of immunoglobulin is well established as a treatment for patients with antibody deficiency and for patients requiring immunomodulation. Although efficacy is believed to be equivalent for the different immunoglobulin products, it is generally regarded as best practice not...

Full description

Saved in:
Bibliographic Details
Published inClinical medicine (London, England) Vol. 19; no. 3; pp. 201 - 204
Main Authors Bethune, Claire, Herriot, Richard
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.05.2019
Royal College of Physicians
Subjects
Accreditation
Censuses
Drug Substitution - adverse effects
Drug Substitution - statistics & numerical data
Drug-Related Side Effects and Adverse Reactions
Generic products
Humans
immunodeficiency
Immunoglobulin
Immunoglobulins
Immunoglobulins - administration & dosage
Immunoglobulins - adverse effects
Immunoglobulins - therapeutic use
Immunologic Deficiency Syndromes - drug therapy
Immunology
immunomodulation
Infections
Manufacturers
Nursing
Original Research
Patients
Product development
Retrospective Studies
United Kingdom
United Kingdom
United Kingdom > UK
England
immunomodulation
Immunoglobulin
immunodeficiency
Online AccessGet full text

Cover

More Information
Summary:The use of regular infusions of immunoglobulin is well established as a treatment for patients with antibody deficiency and for patients requiring immunomodulation. Although efficacy is believed to be equivalent for the different immunoglobulin products, it is generally regarded as best practice not to switch from one product to another unless there is a clinical reason to change. Changes in commissioning guidance and issues with the supply of some immunoglobulin products to the UK resulted in a requirement for a significant number of patients to switch between immunoglobulin products in 2017–2018. Data from the 2018 UK Primary Immunodeficiency census has been used to evaluate the clinical results of switching. Results from 30 immunology centres reported a total of 802 immunoglobulin product switches. Twelve reactions were recorded, none of which required admission to hospital, one patient was treated with oral corticosteroids, the others required either no treatment or treatment with oral antihistamines. This review of immunoglobulin product switch reactions gives a clearer indication regarding the safety of product switching than has previously been published.
ISSN:1470-2118
1473-4893
DOI:10.7861/clinmedicine.19-3-201